Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

Zoledronic acid (ZOL), belonging to third generation bisphosphonate family, is a potent inhibitor of osteoclast-mediated bone resorption, widely used to effectively prevent osteolysis in breast cancer patients who develop bone metastases. Low doses of ZOL have been shown to exhibit a direct anticanc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Fanale, Daniele, Amodeo, Valeria, Bazan, Viviana, Insalaco, Lavinia, Incorvaia, Lorena, Barraco, Nadia, Castiglia, Marta, Rizzo, Sergio, Santini, Daniele, Giordano, Antonio, Castorina, Sergio, Russo, Antonio
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5045398/
https://ncbi.nlm.nih.gov/pubmed/27081088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8722
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares